Tislelizumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer

Uterine Cervical Neoplasms Clinical Trial

Official title:

Tislelizumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer: a Prospective, Single-arm, Single-center, Phase II Clinical Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05588219
• Other study ID #: 2022-K046-01
• Status: Recruiting
• Phase: Phase 2
• Start date: December 1, 2022
• Est. completion date: December 31, 2025

Study information

• Verified date: November 2023
• Source: First Affiliated Hospital of Guangxi Medical University
• Contact: Yong Zhang, PhD
• Phone: 13607884001
• Email: zhangyonggx[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study aims to evaluate the efficacy and safety of Tislelizumab combined with concurrent chemoradiotherapy in the treatment of cervical cancer patients with cervical mass > 4cm and regional lymph node metastasis, paracervical invasion and regional lymph node metastasis, stage IIIA, stage IIIB, and stage IVA. To provide a clinical reference for finding a safe and effective individualized treatment plan to improve the survival prognosis of locally advanced cervical cancer patients.

Description:

This is a prospective, single-arm, single-center phase II clinical study. The objective is to evaluate the efficacy and safety of Tislelizumab combined with concurrent chemoradiotherapy in the treatment of locally advanced cervical cancer. This study was independently completed by our center. Cervical cancer patients with cervical mass > 4cm with regional lymph node metastasis, paracervical invasion with regional lymph node metastasis, stage IIIA, stage IIIB and stage IVA in FIGO stage 2018 were selected as subjects, and 30 patients were planned to be enrolled. External irradiation 45~50Gy/25f+ Brachytherapy 28~30Gy/4~5f; Chemotherapy: DDP 40mg/m2/W, synchronous with radiotherapy, complete at least 4 cycles; Tislelizumab: 200mg/3W for 1 year or disease progression or intolerable toxicity, whichever occurs first.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: December 31, 2025
• Est. primary completion date: December 31, 2024
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. Aged 18 to 70 years.

2. The pathological types of cervical cancer confirmed by histopathology were squamous cell carcinoma, adenocarcinoma and adenosquamous cell carcinoma.

3. In FIGO stage 2018, cervical mass > 4cm with regional lymph node metastasis, paracervical invasion with regional lymph node metastasis, stage IIIA, stage IIIB, and stage IVA.

4. Having at least one measurable lesion according to RECIST 1.1.

5. ECOG score 0-1.

6. Expected survival time =6 months.

7. Major organ function is normal, that is, meeting the following criteria: blood routine: HB=90g/L, ANC=1.5×109/L, PLT=80×109/L; Biochemical examination of ALB=30g/L, TBIL=1.5 ULN, ALT and AST=2.5 ULN, plasma Cr=1.5 ULN or creatinine clearance =60 ml/min.

8. Menopausal women, or women of childbearing age who meet all the following conditions:

non-lactation, not pregnant, and can take adequate contraceptive measures during the study treatment.

9. Subjects volunteered to join the study, signed the informed consent, had good compliance, and cooperated with follow-up.

Exclusion Criteria:

1. Patients have had or currently have other malignant tumors within 5 years.

2. Patients allergic or sensitive to any drug in the study protocol.

3. Patients innate or acquired immune deficiency (e.g. HIV infection).

4. The presence of any active, known or suspected autoimmune disease (such as, but not limited to, interstitial pneumonia, uveitis, enteritis, hepatitis, arthritis, nephritis, hypophysitis, hyperthyroidism, hypothyroidism, etc.); The subject had vitiligo. Subjects with asthma require bronchodilators for medical intervention.

5. The presence of active infections requiring systemic treatment.

6. The subject has previously received other PD-1 or PD-L1, or CTLA-4 antibody therapy, or other drug therapy targeting immunoregulatory receptor preparations.

7. Unrelieved toxic effects above CTCAE grade 1 due to any previous treatment, excluding alopecia.

8. Patients with a history of myocardial infarction or stroke, unstable angina pectoris, decompensated heart failure or deep vein thrombosis.

9. Patients with long-term untreated wounds or fractures, major surgical operations or severe traumatic injuries, fractures or ulcers within 4 weeks.

10. Pregnant or lactating women.

11. Patients with liver and kidney dysfunction.

12. Patients with a history of abuse of psychotropic drugs and unable to abstain or patients with mental disorders.

13. Patients who have participated in clinical trials of other drugs within 4 weeks.

14. Patients with concomitant diseases that, in the judgment of the investigator, seriously endanger the patient's safety or affect the patient's completion of the study.

15. The investigator judged that participation in this study was not conducive to the maximum benefit of the subjects.

Related Conditions & MeSH terms

• Uterine Cervical Neoplasms

Intervention

Drug:
• Tislelizumab
Tislelizumab injection[10ml:100mg] will be used beginning with radiotherapy: 200mg/3W for 1 year or disease progression or intolerable toxicity, whichever occurs first.
• DDP synchronous with radiotherapy
DDP 40mg/m2/W, synchronous with radiotherapy, complete at least 4 cycles.

Locations

Country	Name	City	State
China	First Affiliated Hospital of Guangxi Medical University	Nanning	Guangxi

Sponsors (1)

Lead Sponsor	Collaborator
Yong Zhang,MD

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Tumor regression ratio	The tumor regression ratio after external irradiation, MRI/CT will be used for evaluating the carcinoma status.	2 weeks
Secondary	Overall Response Rate	The overall response rate or tumor after radiotherapy and chemotherapy, and MRI/CT will be used for evaluating the carcinoma status.	3 months, 6 moths
Secondary	Overall Survival	OS was calculated from the date of entry into the study to the date of death or the last follow-up visit.	1 years, 3 years
Secondary	Progression Free Survival	PFS was calculated from the date of entry into the study to the date of first physical or radio-graphic evidence of disease progression, death or the last follow-up visit.	1 years, 3 years